Bruker launches MyGenius Pro MDx system
May 2026—Bruker’s microbiology and infection diagnostics division launched at ESCMID Global (April 17–21, Munich) the MyGenius Pro system in Europe.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Sarstedt awarded innovative technology contract
May 2026—Sarstedt’s Tempus1800 sample transport system was awarded a Vizient innovative technology contract.
City of Hope to evaluate Quest Haystack MRD test
May 2026—City of Hope is implementing Quest Diagnostics’ Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial patients with solid tumor cancers to help guide disease management for breast, colorectal, ovarian, and prostate cancer.
Hardy Dx gets breakthrough designation for AMR assays
April 2026—The Food and Drug Administration has granted breakthrough device designation to the NG-Test Candida auris and NG-Test Acineto-5 assays, which are developed and manufactured in France by NG Biotech and distributed exclusively in the United States by Hardy Diagnostics.
Fujirebio, Sysmex to sell products for dementia testing
April 2026—Fujirebio and Sysmex have agreed on a sales collaboration in which Sysmex will exclusively sell Fujirebio’s fully automated Lumipulse immunoassay systems and reagents for dementia testing.
Idylla CDx MSI test gets European IVDR certification
April 2026—Biocartis’ Idylla CDx MSI test has received class C companion diagnostic certification under the European Union IVDR.
FDA clears Randox clinical drug testing panel
April 2026—The Food and Drug Administration has granted 510(k) clearance for Randox USA’s clinical drug testing panel.
Proscia earns top score in KLAS digital pathology report
April 2026—A new report from KLAS Research awarded Proscia the highest overall performance score (95.2) in the U.S. market, based on customer feedback.
Leica Biosystems launches Aperio GT Elite scanner
April 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
Thermo Fisher introduces LDT for tacrolimus dosing
April 2026—Thermo Fisher Scientific launched the TacroType pharmacogenetic test, a laboratory-developed test designed to help inform clinicians on dosing tacrolimus, an immunosuppressive drug for transplant recipients.